EGFR H835L

CI-VAR-00001939Explore in graph →CIViC 5521

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Adenocarcinoma1
EGFR L833V AND EGFR H835L	Firmonertinib	Predictive	C	Supports Sensitivity Response	2	submitted	EID13093 Two patients with advanced lung adenocarcinoma harboring the EGFR L833V/H835L compound mutation received first-line furmonertinib (80 mg once daily), and both achieved partial responses according to R… (full text at CIViC) PMID 40963567 · Wang et al., 2025 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.